RSV vaccine effective in preventing hospitalizations in older Americans
Today, The Lancet published the first real-world data analysis of respiratory syncytial virus (RSV) vaccine efficacy among older US adults in a large multistate study. The study shows the vaccine was 80% effective in protecting against hospitalizations and deaths during the 2023-2024 RSV season.
RSV Vaccine Shows Strong Protection for Older Adults
A large new study says the RSV vaccine is 80% effective at preventing hospitalization in older adults due to complications from the illness, and works just as well at protecting them from death or needing intensive care unit support for severe complications.
Abrysvo Vaccine Highly Effective Against RSV-Related Hospitalization in Older Adults
The RSV vaccine Abrysvo was highly effective against hospital and ED encounters in a large cohort of older adults with comorbidities and immunocompromising conditions.
RSV Vaccine Proves Highly Effective for Older Adults
A multi-state study, published in The Lancet, is one of the first real world data analyses of the effectiveness of the RSV -- short for respiratory
RSV can be deadly, especially for older adults. What to know about symptoms and the new vaccine
First discovered in chimpanzees in 1956 and in children the following year, respiratory syncytial virus (RSV) isn’t new. Neither is it uncommon among the youngest and oldest populations, infecting most babies and toddlers before their second birthday and accounting for the annual hospitalization of up to 160,000 U.S. adults 60 and older.
Study confirms RSV vaccine's protective power for seniors
A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization.
Yahoo8d
New RSV vaccine guidelines: Adults 75+ urged to vaccinate
AUSTIN (KXAN) — In 2023, the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) ...
infectiousdiseaseadvisor.com1d
Investigational RSV Vaccine mRNA-1345: Revaccination Safe in Eligible Older Adults
There were no safety concerns identified among older adults following revaccination with the investigational respiratory syncytial virus vaccine mRNA-1345, and immune responses elicited by ...
Managed Healthcare Executive10d
Of Mice, Muscles, Older Adults and RSV
However, in the setting of severe respiratory infections, susceptible older adults experience faster muscle deterioration ...
Merck's RSV antibody for infants effective in reducing some types of infections in study
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...
BioSpace1d
Merck, Pfizer Tout Promising Respective Data in RSV With High Rates of Prevention
Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...